Prof Nagi El Saghir speaks to ecancer in an online interview for the virtual BGICC 2021 meeting about BRCA mutation in metastatic triple negative breast cancer (TNBC) patients.

Prof El Saghir begins by explaining the outlining the epidemiology of the BRCA mutation and of triple negative breast cancer, before going into the treatment guidelines.

He then highlights the use of PARP inhibitors and immunotherapy in this disease setting and discusses relevant trials evaluating these treatments.